Therefore, the aforementioned novel applications of GLP-1RAs all have the potential to bolster treatment and management options for the field as a whole, and new research continues to illuminate the physiological mechanisms behind this observed neuroprotective effect
The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss
Its not hard to understand why sticking with this regime is challenging a large minority of patients report unpleasant side effects such as nausea and vomiting, and some experience additional side effects such as injection-site reactions, infections, heart burn, and headaches
That matters for side effects, dose timing, surgery planning, and decisions about stopping or switching treatment
Purdue reported Cornell-linked research showing households with at least one GLP-1 user changed how they buy food, with less overall grocery spending and relatively stronger purchase signals for foods like yogurt and fresh produce than for heavier, less nutrient-dense items
They identified gastrointestinal (GI) issues, particularly vomiting and nausea, as the most common side effects for most GLP-1 RAs, while headache and joint pain were most frequently discussed in posts about tirzepatide
